SUBSCRIBE
SUBSCRIBE

Japan

LATEST FROM BIOSPACE
Pictured: Novartis' logo outside its building in S
Business
Novartis, PeptiDream Ink Potential $2.7B Deal to Expand Radioligand Discovery Partnership
Under the latest teaming between the two companies, who have worked together since 2010, Novartis will pay $180 million upfront to PeptiDream to find new radioligand therapies.
April 30, 2024
 · 
2 min read
 · 
Tyler Patchen
Pictured: Boehringer Ingelheim's office in California
Business
Boehringer, Sosei Ink Potential $732M Deal for Schizophrenia Treatment
Boehringer Ingelheim has paid $27.3 million upfront to Sosei Heptares to develop a small molecule agonist of GPR52 to treat the positive, negative and cognitive symptoms of schizophrenia.
March 11, 2024
 · 
2 min read
 · 
Tyler Patchen
PRESS RELEASES
Press Releases
Eisai to Present Dual-Acting Lecanemab Three Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer’s Association International Conference 2024
July 23, 2024
 · 
14 min read
Press Releases
Astellas and Graduate School of Medicine / Faculty of Medicine, Osaka University Enter into Research Collaboration to Develop Pluripotent Stem Cell-Derived Cartilage Organoid Cell Therapy
July 22, 2024
 · 
4 min read
Press Releases
Renalys Pharma Closes ¥6.0Bn Series A Financing to Advance Kidney Disease Treatments Across Asia
July 17, 2024
 · 
3 min read
Press Releases
John Nicols Appointed Strategic Advisor to bitBiome
July 17, 2024
 · 
2 min read
Press Releases
Patent rights jointly owned by the National Cancer Center and the University of Pennsylvania, licensed to ARC Therapies, Inc.
July 11, 2024
 · 
3 min read
Drug Development
ORYZON Receives “Decision to grant” for Two Important Patents for Vafidemstat in Japan
July 9, 2024
 · 
7 min read